| Literature DB >> 28814819 |
Ratnakar N Asolkar1, Ahilya Singh2, Paul R Jensen1, William Aalbersberg2, Brad K Carté2, Klaus-D Feussner2, Ramesh Subramani3, Antonio DiPasquale4, Arnold L Rheingold4, William Fenical1.
Abstract
Six cytotoxic and antimicrobial metabolites of a new <span class="Chemical">bromo-phenazinone class, the <span class="Chemical">marinocyanins A-F (1-6), were isolated together with the known bacterial metabolites <span class="Chemical">2-bromo-1-hydroxyphenazine (7), lavanducyanin (8, WS-9659A) and its chlorinated analog WS-9659B (9). These metabolites were purified by bioassay-guided fractionation of the extracts of our MAR4 marine actinomycete strains CNS-284 and CNY-960. The structures of the new compounds were determined by detailed spectroscopic methods and marinocyanin A (1) was confirmed by crystallographic methods. The marinocyanins represent the first bromo-phenazinones with an N-isoprenoid substituent in the skeleton. Marinocyanins A-F show strong to weak cytotoxicity against HCT-116 human colon carcinoma and possess modest antimicrobial activities against Staphylococcus aureus and amphotericin-resistant Candida albicans.Entities:
Keywords: Bromophenazinones; MAR4 actinomycete; Meroterpenoids
Year: 2017 PMID: 28814819 PMCID: PMC5555602 DOI: 10.1016/j.tet.2017.03.003
Source DB: PubMed Journal: Tetrahedron ISSN: 0040-4020 Impact factor: 2.457